FullCircle Wealth’s Amicus Therapeutics FOLD Stock Holding History

FullCircle Wealth’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-11,793	Closed	-$136K	–	224
2024 Q3	$136K	Buy	+11,793	New	+$128K	0.06%	179

Other funds holding FOLD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FullCircle Wealth's FOLD Position: Q4 2024 in Review

FullCircle Wealth sold out of Amicus Therapeutics (FOLD) in Q4 2024, closing a stake of 11,793 shares — an estimated $136K sold.

FullCircle Wealth first reported a position in FOLD in Q3 2024 and held it in 1 quarter. The position peaked at $136K in Q3 2024. 290 funds tracked by Wall St. Rank hold FOLD as of Q4 2024.

FullCircle Wealth reported no remaining Amicus Therapeutics position as of Q4 2024 after selling out during the quarter.
FullCircle Wealth sold 11,793 Amicus Therapeutics shares in Q4 2024, an estimated $136K.
FullCircle Wealth first reported a position in Amicus Therapeutics in Q3 2024 and held it in 1 quarter.
FullCircle Wealth's Amicus Therapeutics position peaked at $136K in Q3 2024.
290 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2024.

Based on FullCircle Wealth's 13F filing for Q4 2024, filed 14 Feb 2025.